Abbott enrolls first U.S. patient in global EXCEL trial
4 October 2011 | By Abbott
Abbott's EXCEL is the largest trial to date designed to evaluate optimal treatment strategy in patients with unprotected left main disease...
List view / Grid view
4 October 2011 | By Abbott
Abbott's EXCEL is the largest trial to date designed to evaluate optimal treatment strategy in patients with unprotected left main disease...
3 October 2011 | By Ogilvy Healthworld UK Limited
Pfizer announce the launch of BeneFIX® with Room Temperature Storage (RTS)....
3 October 2011 | By B&W Tek
B&W Tek, Inc., is proud to introduce the NanoRam™...
29 September 2011 | By Takeda Pharmaceutical Company Limited
The CHMP has issued a positive opinion for EdarbiTM (azilsartan medoxomil)...
27 September 2011 | By kdm communications limited
Tecan has launched a new generation of high quality MCA 384 Disposable Tips...
27 September 2011 | By Boehringer Ingelheim
Results from a Phase I/II study...
27 September 2011 | By Novartis
Novartis has received regulatory approval in Japan for once-daily Gilenya (fingolimod)...
27 September 2011 | By Novartis
Novartis has presented new Phase III data at the ERS congress...
26 September 2011 | By Buchi
The Encapsulator B-390 & B-395 Pro, are designed for the immobilization of enzymes, drugs...
26 September 2011 | By Boehringer Ingelheim
Boehringer Ingelheim will establish a new separate business for the development and commercialization of own biosimilars...
26 September 2011 | By The Scott Partnership
Field Flow Fractionation (FFF) technology announced...
26 September 2011 | By Eli Lilly and Company
New data from PARAMOUNT study shows benefit in this hard-to-treat population...
26 September 2011 | By Novartis
Afinitor® more than doubled the time women lived without tumor growth...
26 September 2011 | By Eli Lilly and Company
CHMP has issued a positive opinion for the use of ALIMTA® as continuation maintenance therapy for deadly form of lung cancer...
26 September 2011 | By AstraZeneca
AstraZeneca announced that FASLODEX™ (fulvestrant) has received regulatory approval...